Kiwi Wealth Investments Limited Partnership lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 66.1% during the first quarter, Holdings Channel reports. The institutional investor owned 64,265 shares of the biopharmaceutical company’s stock after selling 125,098 shares during the quarter. Kiwi Wealth Investments Limited Partnership’s holdings in Gilead Sciences were worth $4,845,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Archford Capital Strategies LLC acquired a new position in Gilead Sciences during the first quarter worth approximately $106,000. Certified Advisory Corp acquired a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $133,000. Advisors Preferred LLC acquired a new position in shares of Gilead Sciences in the first quarter valued at approximately $140,000. Stelac Advisory Services LLC acquired a new position in shares of Gilead Sciences in the first quarter valued at approximately $141,000. Finally, Mckinley Capital Management LLC Delaware grew its position in shares of Gilead Sciences by 67.7% in the first quarter. Mckinley Capital Management LLC Delaware now owns 2,130 shares of the biopharmaceutical company’s stock valued at $161,000 after purchasing an additional 860 shares during the last quarter. 77.71% of the stock is currently owned by hedge funds and other institutional investors.

GILD has been the topic of several research reports. Zacks Investment Research downgraded Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, April 11th. Royal Bank of Canada reaffirmed a “buy” rating and issued a $94.00 target price on shares of Gilead Sciences in a research report on Friday, February 23rd. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, May 2nd. ValuEngine downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, May 2nd. Finally, BidaskClub raised Gilead Sciences from a “strong sell” rating to a “sell” rating in a research report on Wednesday, June 6th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $88.00.

Gilead Sciences opened at $70.78 on Thursday, according to MarketBeat.com. The company has a debt-to-equity ratio of 1.32, a current ratio of 2.84 and a quick ratio of 2.75. Gilead Sciences, Inc. has a fifty-two week low of $63.76 and a fifty-two week high of $89.54. The firm has a market cap of $93.40 billion, a price-to-earnings ratio of 8.25, a price-to-earnings-growth ratio of -6.25 and a beta of 1.15.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, May 1st. The biopharmaceutical company reported $1.48 earnings per share for the quarter, missing the consensus estimate of $1.67 by ($0.19). Gilead Sciences had a return on equity of 45.49% and a net margin of 14.03%. The business had revenue of $5.09 billion for the quarter, compared to the consensus estimate of $5.40 billion. During the same quarter in the previous year, the company earned $2.23 earnings per share. The firm’s revenue for the quarter was down 21.8% on a year-over-year basis. analysts predict that Gilead Sciences, Inc. will post 5.75 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 28th. Stockholders of record on Friday, June 15th will be paid a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.22%. The ex-dividend date is Thursday, June 14th. Gilead Sciences’s payout ratio is 26.64%.

In related news, Director John C. Martin sold 50,000 shares of the firm’s stock in a transaction on Friday, June 1st. The stock was sold at an average price of $68.13, for a total transaction of $3,406,500.00. Following the completion of the transaction, the director now directly owns 3,067,762 shares of the company’s stock, valued at approximately $209,006,625.06. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director John Francis Cogan sold 5,833 shares of the firm’s stock in a transaction on Friday, March 16th. The stock was sold at an average price of $80.09, for a total value of $467,164.97. Following the transaction, the director now directly owns 58,452 shares of the company’s stock, valued at $4,681,420.68. The disclosure for this sale can be found here. Insiders sold a total of 190,834 shares of company stock valued at $13,693,989 over the last quarter. 1.16% of the stock is owned by corporate insiders.

Gilead Sciences Company Profile

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.